Cargando…

Genetic and RNA-related molecular markers of trastuzumab-chemotherapy-associated cardiotoxicity in HER2 positive breast cancer: a systematic review

Cancer-therapy related cardiotoxicity (CTRCT) is a significant and frequent complication of monoclonal antibody directed therapy, especially Trastuzumab, for human epidermal growth factor receptor 2 (HER2) overexpressing breast cancers. Reliable, clinically available molecular predictive markers of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lunardi, Mattia, Al-Habbaa, Ahmed, Abdelshafy, Mahmoud, Davey, Matthew G., Elkoumy, Ahmed, Ganly, Sandra, Elzomor, Hesham, Cawley, Christian, Sharif, Faisal, Crowley, James, Kerin, Michael, Wijns, William, Lowery, Aoife, Soliman, Osama
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9004047/ https://www.ncbi.nlm.nih.gov/pubmed/35413811 http://dx.doi.org/10.1186/s12885-022-09437-z

Ejemplares similares

Heart Failure Association-International Cardio-Oncology Society Risk Score Validation in HER2-Positive Breast Cancer
por: Cronin, Michael, et al.
Publicado: (2023)

Perioperative Levosimendan Infusion in Patients With End-Stage Heart Failure Undergoing Left Ventricular Assist Device Implantation
por: Abdelshafy, Mahmoud, et al.
Publicado: (2022)

Temporary Right-Ventricular Assist Devices: A Systematic Review
por: Abdelshafy, Mahmoud, et al.
Publicado: (2022)

Case report: Transcatheter aortic valve replacement in a large bicuspid anatomy using the XL-Myval 32 mm
por: Elkoumy, Ahmed, et al.
Publicado: (2022)

Multimodal Imaging of Cancer Therapy-Related Cardiac Dysfunction in Breast Cancer—A State-of-the-Art Review
por: Cronin, Michael, et al.
Publicado: (2023)

Paravalvular Aortic Regurgitation Severity Assessed by Quantitative Aortography: ACURATE neo2 versus ACURATE neo Transcatheter Aortic Valve Implantation
por: Rück, Andreas, et al.
Publicado: (2021)

Safety and Efficacy of Myval Implantation in Patients with Severe Bicuspid Aortic Valve Stenosis—A Multicenter Real-World Experience
por: Elkoumy, Ahmed, et al.
Publicado: (2022)

Cardiotoxicity of trastuzumab in patients with HER2-positive gastric cancer
por: Soo Park, Ji, et al.
Publicado: (2017)

Differential impact of hormone receptor status on survival and recurrence for HER2 receptor-positive breast cancers treated with Trastuzumab
por: McGuire, Andrew, et al.
Publicado: (2017)

Core Lab Adjudication of the ACURATE neo2 Hemodynamic Performance Using Computed-Tomography-Corrected Left Ventricular Outflow Tract Area
por: Elkoumy, Ahmed, et al.
Publicado: (2022)

3D-based strain analysis and cardiotoxicity detection in cancer patients received chemotherapy
por: Azzam, Muhammad, et al.
Publicado: (2023)

Acute and chronic exercise training in patients with Class II pulmonary hypertension: effects on haemodynamics and symptoms
por: Lunardi, Mattia, et al.
Publicado: (2022)

Pro1170 Ala polymorphism in HER2-neu is associated with risk of trastuzumab cardiotoxicity
por: Stanton, Sasha E, et al.
Publicado: (2015)

The Research Progress of Trastuzumab-Induced Cardiotoxicity in HER-2-Positive Breast Cancer Treatment
por: Lin, Mengmeng, et al.
Publicado: (2022)

Mild Cardiotoxicity and Continued Trastuzumab Treatment in the Context of HER2-Positive Breast Cancer
por: de la Brassinne Bonardeaux, Orianne, et al.
Publicado: (2023)

One-Year Outcomes after Myval Implantation in Patients with Bicuspid Aortic Valve Stenosis—A Multicentre Real-World Experience
por: Elkoumy, Ahmed, et al.
Publicado: (2023)

Predictors of Conduction Disturbances Requiring New Permanent Pacemaker Implantation following Transcatheter Aortic Valve Implantation Using the Evolut Series
por: Abdelshafy, Mahmoud, et al.
Publicado: (2023)

Overview of MicroRNA Expression in Predicting Response to Neoadjuvant Therapies in Human Epidermal Growth Receptor-2 Enriched Breast Cancer – A Systematic Review
por: Davey, Matthew G, et al.
Publicado: (2022)

Efficacy of levosimendan infusion in patients undergoing a left ventricular assist device implant in a propensity score matched analysis of the EUROMACS registry—the Euro LEVO-LVAD study
por: Abdelshafy, Mahmoud, et al.
Publicado: (2023)

Trastuzumab Cardiotoxicity in Patients with Breast Cancer
por: Freitas, Aguinaldo Figueiredo, et al.
Publicado: (2014)

Unexpected Cardiotoxicity in Patients With HER2-Mutant NSCLC Treated With Trastuzumab Deruxtecan: A Case Report
por: Riudavets, Mariona, et al.
Publicado: (2022)

Coq10 for preventing cardiotoxicity in breast cancer patients treated with trastuzumab
por: Al-Hammadi, Nawal, et al.
Publicado: (2023)

The influence of steroid receptor status on the cardiotoxicity risk in HER2-positive breast cancer patients receiving trastuzumab
por: Huszno, Joanna, et al.
Publicado: (2015)

Influence of Ile655Val polymorphism on trastuzumab-induced cardiotoxicity in early-stage HER2 positive breast cancer
por: Vazdar, Ljubica, et al.
Publicado: (2021)

Cardiotoxicity is mitigated after a supervised exercise program in HER2-positive breast cancer undergoing adjuvant trastuzumab
por: Jacquinot, Quentin, et al.
Publicado: (2022)

Cardiotoxicity of concomitant radiotherapy and trastuzumab for early breast cancer
por: Marinko, Tanja, et al.
Publicado: (2014)

A Case of Trastuzumab-Associated Cardiomyopathy Presenting as an Acute Coronary Syndrome: Acute Trastuzumab Cardiotoxicity
por: Hidalgo, Sylvana, et al.
Publicado: (2013)

The Clinical Efficacy and Cardiotoxicity of Fixed-Dose Monthly Trastuzumab in HER2-Positive Breast Cancer: A Single Institutional Analysis
por: Wu, Yi-Ying, et al.
Publicado: (2016)

MicroRNA Expression Profiles and Breast Cancer Chemotherapy
por: Davey, Matthew G., et al.
Publicado: (2021)

Detection of Subclinical Trastuzumab-Induced Cardiotoxicity in Patients with Breast Cancer
por: dos Santos, Marília Harumi Higuchi
Publicado: (2013)

Doxorubicin‐induced and trastuzumab‐induced cardiotoxicity in mice is not prevented by metoprolol
por: Nicol, Martin, et al.
Publicado: (2021)

Ginsenoside Rg2 Attenuated Trastuzumab-Induced Cardiotoxicity in Rats
por: Liu, Guang, et al.
Publicado: (2022)

Trastuzumab-related cardiotoxicity: what do we know in 2020?
por: Liu, Jia, et al.
Publicado: (2020)

Risks of trastuzumab‐related cardiotoxicity in breast cancer patients in Taiwan
por: Chang, Wei‐Ting, et al.
Publicado: (2021)

Antioxidant Protection against Trastuzumab Cardiotoxicity in Breast Cancer Therapy
por: Méndez-Valdés, Gabriel, et al.
Publicado: (2023)

Mechanisms of trastuzumab induced cardiotoxicity – is exercise a potential treatment?
por: Eaton, Holden, et al.
Publicado: (2023)

Three-Year Outcomes Following Permissive Cardiotoxicity in Patients on Trastuzumab
por: Zhou, Shijie, et al.
Publicado: (2023)

Relevance of the 21-gene expression assay in male breast cancer: A systematic review and meta-analysis
por: Davey, Matthew G., et al.
Publicado: (2022)

Cardiotoxicity during long-term trastuzumab use in patients with HER2-positive metastatic breast cancer: who needs cardiac monitoring?
por: Bouwer, N. I., et al.
Publicado: (2021)

Evaluation of the Preventive Effects of Carvedilol on Trastuzumab-Induced Cardiotoxicity in Early-Stage and Locally Advanced HER2-Positive Breast Cancer Patients
por: Esfandbod, Mohsen, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_fao4060cvv4av9qdrsnfpkirq6